Metastatic prostate cancer: hormone dependency and therapeutic efficacy of GnRH analogues

Tolis, G.; Koutsilieris, Michael; Stellos, A.; Fazekas, A. T. A.; Klioze, Sol S.; Yakabow, A.; Adenauer, Hannah

doi:10.1530/acta.0.107s0022

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, up to 25% of patients will recur, heralded by a biochemical recurrence measured as a rising PSA, and require secondary treatment. Prostate tumours depend on androgen signalling for growth and survival, and this dependence has rationalised the standard treatment for metastatic prostate cancer, androgen-deprivation therapy (ADT), for decades [105, 106]. The most common method of ADT uses luteinising hormone-releasing hormone (LHRH) agonists or antagonists to medically disrupt hypogonadal feedback loop to inhibit testicular testosterone production, or to a lesser degree direct orchiectomy.…”

Section: Prostate Cancer As a Candidate For Insulin-lowering Therapymentioning

confidence: 99%

New Players for Advanced Prostate Cancer and the Rationalisation of Insulin-Sensitising Medication

Gunter

Sarkar

Lubik

et al. 2013

International Journal of Cell Biology

View full text Add to dashboard Cite

Obesity and type 2 diabetes are recognised risk factors for the development of some cancers and, increasingly, predict more aggressive disease, treatment failure, and cancer-specific mortality. Many factors may contribute to this clinical observation. Hyperinsulinaemia, dyslipidaemia, hypoxia, ER stress, and inflammation associated with expanded adipose tissue are thought to be among the main culprits driving malignant growth and cancer advancement. This observation has led to the proposal of the potential utility of “old players” for the treatment of type 2 diabetes and metabolic syndrome as new cancer adjuvant therapeutics. Androgen-regulated pathways drive proliferation, differentiation, and survival of benign and malignant prostate tissue. Androgen deprivation therapy (ADT) exploits this dependence to systemically treat advanced prostate cancer resulting in anticancer response and improvement of cancer symptoms. However, the initial therapeutic response from ADT eventually progresses to castrate resistant prostate cancer (CRPC) which is currently incurable. ADT rapidly induces hyperinsulinaemia which is associated with more rapid treatment failure. We discuss current observations of cancer in the context of obesity, diabetes, and insulin-lowering medication. We provide an update on current treatments for advanced prostate cancer and discuss whether metabolic dysfunction, developed during ADT, provides a unique therapeutic window for rapid translation of insulin-sensitising medication as combination therapy with antiandrogen targeting agents for the management of advanced prostate cancer.

show abstract

Section: Prostate Cancer As a Candidate For Insulin-lowering Therapymentioning

confidence: 99%

New Players for Advanced Prostate Cancer and the Rationalisation of Insulin-Sensitising Medication

Gunter

Sarkar

Lubik

et al. 2013

International Journal of Cell Biology

View full text Add to dashboard Cite

show abstract

Suppression of testicular steroidogenesis by the GnRH agonistic analogue buserelin (HOE-766) in patients with prostatic cancer: Studies in relation to dose and route of administration

Tolis¹,

Faure

Koutsilieris³

et al. 1983

Journal of Steroid Biochemistry

View full text Add to dashboard Cite

Metastatic prostate cancer: hormone dependency and therapeutic efficacy of GnRH analogues

Cited by 2 publications

References 0 publications

New Players for Advanced Prostate Cancer and the Rationalisation of Insulin-Sensitising Medication

New Players for Advanced Prostate Cancer and the Rationalisation of Insulin-Sensitising Medication

Suppression of testicular steroidogenesis by the GnRH agonistic analogue buserelin (HOE-766) in patients with prostatic cancer: Studies in relation to dose and route of administration

Contact Info

Product

Resources

About